That’s not all food ceo Thanks to high-demand weight loss drugs like Ozempic, these are the people who have to worry about their bottom line. There is also reason to be concerned about heavy amounts of tobacco and alcohol.
A new report from Morgan Stanley finds that people using GLP-1 drugs (such as Ozempic, Wigoby, Munjaro, and Zepbound) reduce their tobacco and alcohol intake while taking the drugs. It has been found. GLP-1 is a type of diabetes and weight loss drug that has recently received attention (and explosive sales numbers) for its ability to suppress the user’s appetite.
The investment bank also surveyed about 300 GLP-1 users about their spending habits while taking the drug. Analysts at the bank previously said that the increased use of GLP-1 Long-term pressure on fast food sales, as users report spending less at restaurants.However, their research also found that Users are reducing their tobacco and alcohol intake.
Can weight loss drugs help users reduce the amount they smoke and drink?
40% A higher proportion of survey respondents said they smoked cigarettes at least weekly before starting GLP-1 treatment. After starting treatment, that number decreased to 24%. Meanwhile, weekly e-cigarette use decreased from 30% to 16% of respondents after starting to take GLP-1.
Morgan Stanley found similar results when it asked respondents about their alcohol use. Approximately 56-62% of alcohol consumers taking GLP-1 report drinking less About 14 to 18 percent completely reduced their alcohol intake since starting the medication.
Analysts said they were “cautious about drawing conclusions” from research on the effects of GLP-1 drugs on addictive behavior. However, there is anecdotal evidence from patients and health care providers suggesting that GLP-1 can help curb addiction to alcohol and tobacco. Although research has not yet proven a causal relationship between the two, clinical trial the current Research is underway to better understand the effects of GLP-1 on alcohol and tobacco consumption.
Additionally, Morgan Stanley doesn’t expect the GLP-1 enthusiasm to wane anytime soon. The global market for GLP-1 drugs is projected to reach $105 billion by 2030. Additionally, these drugs are projected to be adopted by approximately 31.5 million people in the United States (approximately 9% of the U.S. population) by 2035.
